Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma

Background: CD19-directed chimeric antigen receptor (CAR) T cells have substantial benefit in the treatment of patients with B-cell malignancies. However, despite encouraging therapeutic efficiency, there is limited overall response rate when anti-CD19 CAR-T cells are used to treat patients with rel...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Onco Targets Ther
Glavni autori: Li, Sujun, Xue, Lei, Wang, Min, Qiang, Ping, Xu, Hui, Zhang, Xuhan, Kang, Wenyao, You, Fengtao, Xu, Hanying, Wang, Yu, Liu, Xin, Yang, Lin, Wang, Xingbing
Format: Artigo
Jezik:Inglês
Izdano: Dove 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635897/
https://ncbi.nlm.nih.gov/pubmed/31372000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S198567
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items